非小细胞肺癌中的MET融合:临床病理特征及对MET抑制的应答
在德国国家基因组医学网络的常规分子筛查中,通过RNA测序鉴定出9例MET融合阳性NSCLC患者,总体频率为0.29%(95%CI:0.15-0.55)。肿瘤均为腺癌,融合伴侣基因包括KIF5B、TRIM4、ST7、PRKAR2B和CAPZA2。4例接受MET酪氨酸激酶抑制剂治疗,2例部分缓解、1例疾病稳定、1例疾病进展。
要点
- MET融合在NSCLC中总体频率为0.29%(95%CI:0.15-0.55),均为腺癌。
- MET融合伴侣基因包括KIF5B、TRIM4、ST7、PRKAR2B和CAPZA2,断点多样。
- 4例接受MET TKI治疗,2例部分缓解、1例疾病稳定、1例疾病进展。
核心结论
- MET融合是NSCLC中非常罕见的致癌驱动事件,主要见于腺癌,融合伴侣和断点具有异质性,MET融合患者可从MET TKI治疗中获益。
研究设计与样本
- 在德国国家基因组医学网络的常规分子筛查项目中,主要通过RNA测序鉴定NSCLC且MET融合阳性的患者,共描述9例患者,其中2例既往已报道。
主要发现
- MET融合总体频率为0.29%(95%CI:0.15-0.55),肿瘤均为腺癌,队列在年龄、性别或吸烟状态方面具有异质性。
- 观察到5种不同融合伴侣基因(KIF5B、TRIM4、ST7、PRKAR2B和CAPZA2)及若干不同断点。
- 4例患者接受MET TKI治疗,结果为2例部分缓解、1例疾病稳定、1例疾病进展。
- 1例患者出现BRAF V600E突变作为获得性耐药机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: MET fusions have been described only rarely in NSCLC. Thus, data on patient characteristics and treatment response are limited. We here report histopathologic data, patient demographics, and treatment outcome including response to MET tyrosine kinase inhibitor (TKI) therapy in MET fusion-positive NSCLC. METHODS: Patients with NSCLC and MET fusions were identified mostly by RNA sequencing within the routine molecular screening program of the national Network Genomic Medicine, Germany. RESULTS: We describe a cohort of nine patients harboring MET fusions. Among these nine patients, two patients had been reported earlier. The overall frequency was 0.29% (95% confidence interval: 0.15-0.55). The tumors were exclusively adenocarcinoma. The cohort was heterogeneous in terms of age, sex, or smoking status. We saw five different fusion partner genes (KIF5B, TRIM4, ST7, PRKAR2B, and CAPZA2) and several different breakpoints. Four patients were treated with a MET TKI leading to two partial responses, one stable disease, and one progressive disease. One patient had a BRAF V600E mutation as acquired resistance mechanism. CONCLUSIONS: MET fusions are very rare oncogenic driver events in NSCLC and predominantly seem in adenocarcinomas. They are heterogeneous in terms of fusion partners and breakpoints. Patients with MET fusion can benefit from MET TKI therapy.
引用
- Riedel R, Fassunke J, Scheel AH, et al. MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition. J Thorac Oncol. 2023. PMID: 37429463. doi:10.1016/j.jtho.2023.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。